vTv Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
vTv Therapeutics Inc. (VTVT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 93.76% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-03-10
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2025 was 93.76%, a 13.67% decline from fiscal 2024.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 108.61%, a 14.32% decline from fiscal 2023.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 126.76%, a 1.52% decline from fiscal 2022.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 128.72%, a 5.36% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|
| 2025-12-31 | 93.76% 10-K · filed 2026-03-10 |
| 2024-12-31 | 108.61% 10-K · filed 2026-03-10 |
| 2023-12-31 | 126.76% 10-K · filed 2026-03-10 |
| 2022-12-31 | 128.72% 10-K · filed 2025-03-20 |
| 2021-12-31 | 122.17% 10-K · filed 2024-03-13 |